Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with M.s.

Multiple Sclerosis

Volumn 14, Issue 2, 2008, Pages 272-273

  Sadiq, Saud A ^a   Rammal, Mustapha ^a   Sara, Gabriel ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

chronic myeloid leukemia; mitoxantrone; multiple sclerosis

Indexed keywords

ALKALINE PHOSPHATASE; BCR ABL PROTEIN; BETA1A INTERFERON; IMATINIB; METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BLADDER DYSFUNCTION; BONE MARROW EXAMINATION; CASE REPORT; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; DRUG INDUCED DISEASE; FATIGUE; FEMALE; HUMAN; LEUKEMIA REMISSION; LEUKOCYTOSIS; LIMB WEAKNESS; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NECK PAIN; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PREGNANCY; RELAPSE; SENSORY DYSFUNCTION; SPINAL CORD LESION; THROMBOCYTOSIS; UNSTEADINESS;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 43149125464     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458507082941     Document Type: Article

References (9)

1. Brassat D., Recher C., Waubant E., Le Page E., Rigal-Huquet F., Laurent G. et al. Therapy-related myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002; 59: 954-5.
2. Cohen BA, Mikol DD Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004; 63: S28-S32.
3. Cordioli C., Cattaneo C., Rossi G. Analysis of incidence, risk factors and prognoiss of acute promyelocytic leukaemia related to mitoxantrone therapy in multiple sclerosis patients. Neurology 2007; 68 (Suppl 1): A276.
4. Rivera V., Al-Sabbagh A., Bennett R., Coyle P., Mikol D., Panitch H. et al. Ongoing Evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis: The RENEW Study. Neurology 2007; 68 (Suppl 1): A275.
5. Morrissey SP, Le Page E., Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J 2005; 12: 74-87.
6. Fox E., Al-Sabbagh A., Bennett R., Sadiq SA Safety and tolerability of Novantrone in clinical practice: status report from the registry to evaluate novantrone effects in worsening MS (RENEW) study. Neurology 2005; 64 (Suppl I): A394.
7. Douglas JR, Robert H. Review of mitoxantrone in the treatment of multiple sclerosis. Neurology 2004; 63: S19-S24.
8. Hartung HP, Gonsette R., Koniq N., Kwiecinski G., Guseo A., Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet 2002; 360: 2018-25.
9. Kerr J., Eisenberg E., Sadiq S. Mitoxantrone therapy-associated menstrual dysfunction in patients with multiple sclerosis. Neurology 2007; 68 (Suppl 1): A275.